Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
MRNA's Cash to Debt is ranked higher than
99% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. MRNA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MRNA' s 10-Year Cash to Debt Range
Min: 0.05  Med: 13.50 Max: No Debt
Current: No Debt
Equity to Asset -0.33
MRNA's Equity to Asset is ranked lower than
95% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MRNA: -0.33 )
Ranked among companies with meaningful Equity to Asset only.
MRNA' s 10-Year Equity to Asset Range
Min: -2  Med: 0.66 Max: 0.95
Current: -0.33
-2
0.95
F-Score: 3
Z-Score: -61.83
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -513.67
MRNA's Operating margin (%) is ranked lower than
72% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. MRNA: -513.67 )
Ranked among companies with meaningful Operating margin (%) only.
MRNA' s 10-Year Operating margin (%) Range
Min: -2259.18  Med: -207.90 Max: -2.56
Current: -513.67
-2259.18
-2.56
Net-margin (%) -0.22
MRNA's Net-margin (%) is ranked higher than
67% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. MRNA: -0.22 )
Ranked among companies with meaningful Net-margin (%) only.
MRNA' s 10-Year Net-margin (%) Range
Min: -2269.84  Med: -226.37 Max: 2.56
Current: -0.22
-2269.84
2.56
ROA (%) -0.02
MRNA's ROA (%) is ranked higher than
74% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. MRNA: -0.02 )
Ranked among companies with meaningful ROA (%) only.
MRNA' s 10-Year ROA (%) Range
Min: -158.44  Med: -64.48 Max: -3.28
Current: -0.02
-158.44
-3.28
Revenue Growth (3Y)(%) -61.50
MRNA's Revenue Growth (3Y)(%) is ranked lower than
86% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MRNA: -61.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRNA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -73  Med: -28.90 Max: 72
Current: -61.5
-73
72
EBITDA Growth (3Y)(%) -62.80
MRNA's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. MRNA: -62.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRNA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -19.25 Max: 49.6
Current: -62.8
0
49.6
EPS Growth (3Y)(%) -61.80
MRNA's EPS Growth (3Y)(%) is ranked lower than
96% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. MRNA: -61.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRNA' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.1  Med: -1.70 Max: 101
Current: -61.8
-82.1
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.89
MRNA's P/E(ttm) is ranked higher than
96% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. MRNA: 3.89 )
Ranked among companies with meaningful P/E(ttm) only.
MRNA' s 10-Year P/E(ttm) Range
Min: 1.9  Med: 3.05 Max: 5
Current: 3.89
1.9
5
PE(NRI) 1.80
MRNA's PE(NRI) is ranked higher than
98% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. MRNA: 1.80 )
Ranked among companies with meaningful PE(NRI) only.
MRNA' s 10-Year PE(NRI) Range
Min: 1.57  Med: 1.99 Max: 2.45
Current: 1.8
1.57
2.45
P/S 12.91
MRNA's P/S is ranked lower than
55% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. MRNA: 12.91 )
Ranked among companies with meaningful P/S only.
MRNA' s 10-Year P/S Range
Min: 0.5  Med: 6.04 Max: 134.19
Current: 12.91
0.5
134.19
Current Ratio 0.38
MRNA's Current Ratio is ranked lower than
95% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. MRNA: 0.38 )
Ranked among companies with meaningful Current Ratio only.
MRNA' s 10-Year Current Ratio Range
Min: 0.03  Med: 3.53 Max: 21.21
Current: 0.38
0.03
21.21
Quick Ratio 0.38
MRNA's Quick Ratio is ranked lower than
94% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. MRNA: 0.38 )
Ranked among companies with meaningful Quick Ratio only.
MRNA' s 10-Year Quick Ratio Range
Min: 0.03  Med: 3.45 Max: 21.07
Current: 0.38
0.03
21.07
Days Sales Outstanding 365.00
MRNA's Days Sales Outstanding is ranked lower than
94% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. MRNA: 365.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRNA' s 10-Year Days Sales Outstanding Range
Min: 0.61  Med: 9.96 Max: 365
Current: 365
0.61
365

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.33
MRNA's Price/Median PS Value is ranked lower than
80% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. MRNA: 2.33 )
Ranked among companies with meaningful Price/Median PS Value only.
MRNA' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 1.57 Max: 22.03
Current: 2.33
0.12
22.03

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing Aug 06 2015 
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies Apr 23 2015 
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based T Dec 18 2014 
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2- Dec 09 2014 
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-i Nov 20 2014 
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
x pie = y Jul 01 2011 
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 

More From Other Websites
MARINA BIOTECH, INC. Financials Aug 26 2015
10-Q for Marina Biotech, Inc. Aug 15 2015
MARINA BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 13 2015
Marina Biotech Announces Second Quarter 2015 Financial Results Aug 13 2015
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Aug 10 2015
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing Aug 06 2015
Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis Aug 05 2015
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 17 2015
Marina Biotech Expands European and Canadian Patent Protection of Its SMARTICLES Nucleic Acid... Jun 10 2015
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... May 14 2015
Marina Biotech Announces First Quarter 2015 Financial Results May 14 2015
Marina Biotech Announces SMARTICLES(R)-Mediated Delivery of a Double-Stranded Oligonucleotide to... May 05 2015
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 27 2015
Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery Technologies Apr 23 2015
Marina Biotech Provides 2014 Year-End Financials and Update Feb 25 2015
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Feb 18 2015
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based... Dec 18 2014
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its... Dec 09 2014
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its... Nov 20 2014
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK